The hospitalization rate and clinical characteristics of mucormycosis prior and during COVID-19 pandemic : A single-center study
Copyright (c) 2023 Mehrdad Estakhr, Zahra Ghotbi, Mahtab Rostamihosseinkhani, Etrat Hooshmandi, Masoud Janipour, Vahid Reza Ostovan, Nima Fadakar, Hanieh Bazrafshan, Zahra Bahrami, Abbas Rahimi-Jaberi, Maryam Poursadeghfard, Masoumeh Nazeri, Pariya Kouhi, Peyman Petramfar, Sadegh Izadi, Zohreh Barzegar, Ehsan Nikzadeh, Sarvin Sasannia, Shahram Arsang-Jang, Reza Tabrizi, Behzad Khademi, Mahsa Kohandel-Shirazi, Mohammad Saied Salehi, Nahid Ashjazadeh, Bijan Khademi, Mohammad Javad Ashraf, Owrang Eilami, Amir Roudgari, Mohsen Moghaddami, Kamiar Zomorodian, Hamid Badali, Afshin Borhani-Haghighi..
INTRODUCTION: There have been some reports of the association between SARS-CoV-2 infection and mucormycosis. This study aims to compare the hospitalization rates and clinical characteristics of mucormycosis before and during the COVID-19 pandemic.
METHODOLOGY: In this retrospective study, we compared the hospitalization rate of mucormycosis patients in Namazi hospital in Southern Iran for two periods of 40 months. We defined July 1st, 2018 to February 17th, 2020, as the pre-COVID-19 period and February 18th, 2020, to September 30th, 2021, as the COVID-19 period. In addition, a quadrupled group of hospitalized patients with age and sex-matched SARS-COV-2 infection without any sign of mucormycosis was selected as the control group for COVID-associated mucormycosis.
RESULT: In the total of 72 mucormycosis patients in the COVID period, 54 patients had a clinical history and a positive RT-PCR, which confirms the diagnosis of SARS-COV2 infection. The hospitalization rate of mucormycosis showed an increase of + 306% (95% CI: + 259%, + 353%) from a monthly average value of 0.26 (95% confidence interval (CI): 0.14, 0.38) in the pre-COVID period to 1.06 in the COVID period. The use of corticosteroids prior to the initiation of hospitalization (p ≤ 0.01), diabetes (DM) (p = 0.04), brain involvement (p = 0.03), orbit involvement (p = 0.04), and sphenoid sinus invasion (p ≤ 0.01) were more common in patients with mucormycosis during the COVID period.
CONCLUSIONS: In high-risk patients, especially diabetics, special care to avoid the development of mucormycosis must be taken into account in patients with SARS-COV-2 infection considered for treatment with corticosteroids.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Journal of infection in developing countries - 17(2023), 6 vom: 30. Juni, Seite 791-799 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 17.07.2023 Date Revised 18.07.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3855/jidc.17371 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359072224 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359072224 | ||
| 003 | DE-627 | ||
| 005 | 20231226080107.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3855/jidc.17371 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1196.xml |
| 035 | |a (DE-627)NLM359072224 | ||
| 035 | |a (NLM)37406065 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Estakhr, Mehrdad |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The hospitalization rate and clinical characteristics of mucormycosis prior and during COVID-19 pandemic |b A single-center study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.07.2023 | ||
| 500 | |a Date Revised 18.07.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright (c) 2023 Mehrdad Estakhr, Zahra Ghotbi, Mahtab Rostamihosseinkhani, Etrat Hooshmandi, Masoud Janipour, Vahid Reza Ostovan, Nima Fadakar, Hanieh Bazrafshan, Zahra Bahrami, Abbas Rahimi-Jaberi, Maryam Poursadeghfard, Masoumeh Nazeri, Pariya Kouhi, Peyman Petramfar, Sadegh Izadi, Zohreh Barzegar, Ehsan Nikzadeh, Sarvin Sasannia, Shahram Arsang-Jang, Reza Tabrizi, Behzad Khademi, Mahsa Kohandel-Shirazi, Mohammad Saied Salehi, Nahid Ashjazadeh, Bijan Khademi, Mohammad Javad Ashraf, Owrang Eilami, Amir Roudgari, Mohsen Moghaddami, Kamiar Zomorodian, Hamid Badali, Afshin Borhani-Haghighi. | ||
| 520 | |a INTRODUCTION: There have been some reports of the association between SARS-CoV-2 infection and mucormycosis. This study aims to compare the hospitalization rates and clinical characteristics of mucormycosis before and during the COVID-19 pandemic | ||
| 520 | |a METHODOLOGY: In this retrospective study, we compared the hospitalization rate of mucormycosis patients in Namazi hospital in Southern Iran for two periods of 40 months. We defined July 1st, 2018 to February 17th, 2020, as the pre-COVID-19 period and February 18th, 2020, to September 30th, 2021, as the COVID-19 period. In addition, a quadrupled group of hospitalized patients with age and sex-matched SARS-COV-2 infection without any sign of mucormycosis was selected as the control group for COVID-associated mucormycosis | ||
| 520 | |a RESULT: In the total of 72 mucormycosis patients in the COVID period, 54 patients had a clinical history and a positive RT-PCR, which confirms the diagnosis of SARS-COV2 infection. The hospitalization rate of mucormycosis showed an increase of + 306% (95% CI: + 259%, + 353%) from a monthly average value of 0.26 (95% confidence interval (CI): 0.14, 0.38) in the pre-COVID period to 1.06 in the COVID period. The use of corticosteroids prior to the initiation of hospitalization (p ≤ 0.01), diabetes (DM) (p = 0.04), brain involvement (p = 0.03), orbit involvement (p = 0.04), and sphenoid sinus invasion (p ≤ 0.01) were more common in patients with mucormycosis during the COVID period | ||
| 520 | |a CONCLUSIONS: In high-risk patients, especially diabetics, special care to avoid the development of mucormycosis must be taken into account in patients with SARS-COV-2 infection considered for treatment with corticosteroids | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a glucocorticoids | |
| 650 | 4 | |a invasive fungal infection | |
| 650 | 4 | |a mucormycosis | |
| 650 | 4 | |a pandemic | |
| 650 | 7 | |a RNA, Viral |2 NLM | |
| 700 | 1 | |a Ghotbi, Zahra |e verfasserin |4 aut | |
| 700 | 1 | |a Rostamihosseinkhani, Mahtab |e verfasserin |4 aut | |
| 700 | 1 | |a Hooshmandi, Etrat |e verfasserin |4 aut | |
| 700 | 1 | |a Janipour, Masoud |e verfasserin |4 aut | |
| 700 | 1 | |a Ostovan, Vahid Reza |e verfasserin |4 aut | |
| 700 | 1 | |a Fadakar, Nima |e verfasserin |4 aut | |
| 700 | 1 | |a Bazrafshan, Hanieh |e verfasserin |4 aut | |
| 700 | 1 | |a Bahrami, Zahra |e verfasserin |4 aut | |
| 700 | 1 | |a Rahimi-Jaberi, Abbas |e verfasserin |4 aut | |
| 700 | 1 | |a Poursadeghfard, Maryam |e verfasserin |4 aut | |
| 700 | 1 | |a Nazeri, Masoumeh |e verfasserin |4 aut | |
| 700 | 1 | |a Kouhi, Pariya |e verfasserin |4 aut | |
| 700 | 1 | |a Petramfar, Peyman |e verfasserin |4 aut | |
| 700 | 1 | |a Izadi, Sadegh |e verfasserin |4 aut | |
| 700 | 1 | |a Barzegar, Zohreh |e verfasserin |4 aut | |
| 700 | 1 | |a Nikzadeh, Ehsan |e verfasserin |4 aut | |
| 700 | 1 | |a Sasannia, Sarvin |e verfasserin |4 aut | |
| 700 | 1 | |a Arsang-Jang, Shahram |e verfasserin |4 aut | |
| 700 | 1 | |a Tabrizi, Reza |e verfasserin |4 aut | |
| 700 | 1 | |a Khademi, Behzad |e verfasserin |4 aut | |
| 700 | 1 | |a Kohandel-Shirazi, Mahsa |e verfasserin |4 aut | |
| 700 | 1 | |a Salehi, Mohammad Saied |e verfasserin |4 aut | |
| 700 | 1 | |a Ashjazadeh, Nahid |e verfasserin |4 aut | |
| 700 | 1 | |a Khademi, Bijan |e verfasserin |4 aut | |
| 700 | 1 | |a Ashraf, Mohammad Javad |e verfasserin |4 aut | |
| 700 | 1 | |a Eilami, Owrang |e verfasserin |4 aut | |
| 700 | 1 | |a Roudgari, Amir |e verfasserin |4 aut | |
| 700 | 1 | |a Moghaddami, Mohsen |e verfasserin |4 aut | |
| 700 | 1 | |a Zomorodian, Kamiar |e verfasserin |4 aut | |
| 700 | 1 | |a Badali, Hamid |e verfasserin |4 aut | |
| 700 | 1 | |a Borhani-Haghighi, Afshin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of infection in developing countries |d 2007 |g 17(2023), 6 vom: 30. Juni, Seite 791-799 |w (DE-627)NLM191178497 |x 1972-2680 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2023 |g number:6 |g day:30 |g month:06 |g pages:791-799 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3855/jidc.17371 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2023 |e 6 |b 30 |c 06 |h 791-799 | ||